Purchase Agilent 1260 Infinity III HPLC System

The National Institutes of Health National Heart, Lung, and Blood Institute seeks to purchase an Agilent 1260 Infinity III HPLC System, with responses due September 4, 2026 at 3:00 PM EST. This is a single-source, non-competitive acquisition under FAR Part 13 (Simplified Acquisition Procedures).

The procurement is set aside for small business; NAICS code is 334516 (Analytical Laboratory Instrument Manufacturing) with a small business size standard of 1,000 employees. Place of performance and delivery details are not specified; offerors must provide a delivery period and F.O.B. point. The proposed award period runs September 28, 2026 through September 27, 2027.

Market research supports the single-source justification on the grounds that the Agilent 1260 Infinity III is the only platform capable of fulfilling NHLBI's complete requirements. The NHLBI Analytical Biochemistry Core Facility requires replacement of an obsolete Agilent 1100 system (in service over 15 years and no longer manufacturer-supported) while maintaining continuity with hemoglobin analytical methodology established since 2013, compatibility with existing Agilent OpenLab/ChemStation software, and longitudinal comparability of research results. Although other HPLC systems possess analytical capabilities, none satisfy the complete requirement without additional method transfer, revalidation, and software migration that would introduce unacceptable risk to ongoing research operations, particularly for the John Tisdale Lab.

Submissions must include unit price, list price, shipping and handling costs, delivery period, prompt payment discount terms, F.O.B. point, DUNS number, TIN, and business size certification. All offerors must maintain active SAM registration. Submit responses via email to Contracting Officer Roxane Burkett at roxane.burkett@nih.gov.